Kyle Gano insider trades: Neurocrine Biosciences (NBIX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kyle reports to the SEC
Open-market buys and sales
49 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | NBIX | ↓ Sell | 36,400 | $132.70 | $4.8M | Direct | Jan 20, 2026 (4d) |
| Nov 4, 2025 | NBIX | ↓ Sell | 300 | $141.97 | $43K | Direct | Nov 4, 2025 (0d) |
| Feb 13, 2025 | NBIX | ↓ Sell | 2,558 | $116.85 | $299K | Direct | Feb 14, 2025 (1d) |
| Feb 10, 2025 | NBIX | ↓ Sell | 980 | $118.39 | $116K | Direct | Feb 12, 2025 (2d) |
| Jan 31, 2025 | NBIX | ↓ Sell | 1,541 | $152.87 | $236K | Direct | Feb 4, 2025 (4d) |
| Jan 15, 2025 | NBIX | ↓ Sell | 65,000 | $141.50 | $9.2M | Direct | Jan 17, 2025 (2d) |
| Feb 13, 2024 | NBIX | ↓ Sell | 1,352 | $132.89 | $180K | Direct | Feb 15, 2024 (2d) |
| Feb 8, 2024 | NBIX | ↓ Sell | 2,580 | $139.16 | $359K | Direct | Feb 8, 2024 (0d) |
| Jan 31, 2024 | NBIX | ↓ Sell | 1,541 | $140.70 | $217K | Direct | Feb 2, 2024 (2d) |
| Jan 2, 2024 | NBIX | ↓ Sell | 75,000 | $131.47 | $9.9M | Direct | Jan 4, 2024 (2d) |
| Aug 21, 2023 | NBIX | ↓ Sell | 2,132 | $107.41 | $229K | Direct | Aug 23, 2023 (2d) |
| Feb 8, 2023 | NBIX | ↓ Sell | 17,004 | $102.79 | $1.7M | Direct | Feb 8, 2023 (0d) |
| Jan 31, 2023 | NBIX | ↓ Sell | 1,541 | $109.98 | $169K | Direct | Feb 2, 2023 (2d) |
| Feb 8, 2022 | NBIX | ↓ Sell | 6,880 | $80.61 | $555K | Direct | Feb 9, 2022 (1d) |
| Jan 5, 2022 | NBIX | ↓ Sell | 28,266 | $85.50 | $2.4M | Direct | Jan 7, 2022 (2d) |
| Feb 8, 2021 | NBIX | ↓ Sell | 6,370 | $115.65 | $737K | Direct | Feb 9, 2021 (1d) |
| Nov 12, 2020 | NBIX | ↓ Sell | 2,257 | $90.73 | $205K | Direct | Nov 16, 2020 (4d) |
| Aug 5, 2020 | NBIX | ↓ Sell | 2,257 | $118.87 | $268K | Direct | Aug 7, 2020 (2d) |
| Apr 24, 2020 | NBIX | ↓ Sell | 1,934 | $99.47 | $192K | Direct | Apr 28, 2020 (4d) |
| Feb 7, 2020 | NBIX | ↓ Sell | 1,623 | $103.33 | $168K | Direct | Feb 11, 2020 (4d) |
| Feb 6, 2020 | NBIX | ↓ Sell | 4,690 | $102.70 | $482K | Direct | Feb 7, 2020 (1d) |
| Feb 6, 2019 | NBIX | ↓ Sell | 762 | $83.56 | $64K | Direct | Feb 8, 2019 (2d) |
| Feb 5, 2019 | NBIX | ↓ Sell | 3,809 | $88.12 | $336K | Direct | Feb 6, 2019 (1d) |
| Aug 1, 2018 | NBIX | ↓ Sell | 28,266 | $115.00 | $3.3M | Direct | Aug 3, 2018 (2d) |
| Mar 5, 2018 | NBIX | ↓ Sell | 23,650 | $90.00 | $2.1M | Direct | Mar 7, 2018 (2d) |
| Feb 5, 2018 | NBIX | ↓ Sell | 2,046 | $83.05 | $170K | Direct | Feb 7, 2018 (2d) |
| Jan 16, 2018 | NBIX | ↓ Sell | 1,625 | $79.05 | $128K | Direct | Jan 18, 2018 (2d) |
| Nov 2, 2017 | NBIX | ↓ Sell | 24,818 | $71.05 | $1.8M | Direct | Nov 6, 2017 (4d) |
| Sep 6, 2017 | NBIX | ↓ Sell | 20,393 | $60.00 | $1.2M | Direct | Oct 3, 2017 (27d) |
| Sep 6, 2017 | NBIX | ↓ Sell | 4,607 | $60.00 | $276K | Direct | Sep 8, 2017 (2d) |
| May 1, 2017 | NBIX | ↓ Sell | 15,000 | $54.00 | $810K | Direct | May 3, 2017 (2d) |
| Apr 12, 2017 | NBIX | ↓ Sell | 13,065 | $50.42 | $659K | Direct | Apr 13, 2017 (1d) |
| Feb 6, 2017 | NBIX | ↓ Sell | 727 | $43.15 | $31K | Direct | Feb 8, 2017 (2d) |
| Feb 3, 2017 | NBIX | ↓ Sell | 1,375 | $42.57 | $59K | Direct | Feb 6, 2017 (3d) |
| Jan 17, 2017 | NBIX | ↓ Sell | 1,625 | $40.65 | $66K | Direct | Jan 18, 2017 (1d) |
| Jan 10, 2017 | NBIX | ↓ Sell | 1,250 | $43.37 | $54K | Direct | Jan 12, 2017 (2d) |
| Apr 11, 2016 | NBIX | ↓ Sell | 41,770 | $44.02 | $1.8M | Direct | Apr 13, 2016 (2d) |
| Feb 3, 2016 | NBIX | ↓ Sell | 1,375 | $37.98 | $52K | Direct | Feb 4, 2016 (1d) |
| Jan 19, 2016 | NBIX | ↓ Sell | 1,625 | $46.84 | $76K | Direct | Jan 21, 2016 (2d) |
| Jan 11, 2016 | NBIX | ↓ Sell | 1,250 | $44.23 | $55K | Direct | Jan 13, 2016 (2d) |
| Oct 16, 2015 | NBIX | ↓ Sell | 25,000 | $47.77 | $1.2M | Direct | Oct 19, 2015 (3d) |
| Jun 1, 2015 | NBIX | ↓ Sell | 38,230 | $42.19 | $1.6M | Direct | Jun 3, 2015 (2d) |
| Jan 16, 2015 | NBIX | ↓ Sell | 1,625 | $30.80 | $50K | Direct | Jan 21, 2015 (5d) |
| Jan 13, 2015 | NBIX | ↓ Sell | 25,000 | $30.00 | $750K | Direct | Jan 15, 2015 (2d) |
| Jan 12, 2015 | NBIX | ↓ Sell | 1,250 | $28.41 | $36K | Direct | Jan 13, 2015 (1d) |
| Dec 17, 2014 | NBIX | ↓ Sell | 4,957 | $22.50 | $112K | Direct | Dec 19, 2014 (2d) |
| Dec 12, 2014 | NBIX | ↓ Sell | 4,043 | $22.50 | $91K | Direct | Dec 15, 2014 (3d) |
| Jan 10, 2014 | NBIX | ↓ Sell | 1,250 | $18.57 | $23K | Direct | Jan 13, 2014 (3d) |
| Sep 4, 2013 | NBIX | ↓ Sell | 2,400 | $15.61 | $37K | Direct | Sep 5, 2013 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NBIX insiders
Open-market trades in the last 12 months
About Kyle Gano's insider trades
Kyle Gano is Chief Executive Officer at Neurocrine Biosciences (NBIX). Since Sep 4, 2013, Kyle has reported no open-market purchases and 49 sales worth $49.5M on SEC Form 4. In the last 12 months: 1 sale ($4.8M).
Their filings also include option exercises (23 filings), grants and awards (15 filings), shares withheld for taxes (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.